Skip to content

Study · Non-randomized trial · n = 110 · 2010

4 results

[Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment].

Gavrilova SI, Kolykhalov IV, Fedorova IaB, Selezneva ND, Kalyn IaB, Roshchina IF, Odinak MM, Emelin AIu, Kashin AV, Gustov AV, Antipenko EA, Korshunova IuA, Davydova TA, Messler G

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2010Cited by 1 (Europe PMC)

PMID20436440 (opens in a new tab)PepBankPUB-20436440
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with mild cognitive impairment, cerebrolysin slowed cognitive deficit progression more than cavinton.

    In plain wordsIn patients with mild cognitive impairment, cerebrolysin slowed thinking decline more than cavinton.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseCognitive deficit progression
    Study

    n = 110

    Comparator
    Cavinton
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The superiority of cerebrolysin over cavinton in slowing down of the cognitive deficit progression and delaying the time or transition of patients to the diagnostic category of Alzheimer's disease was demonstrated.
    2 context sentences
    Summary · context
    The total sample included 110 patients whose mental state met the definition of <> (MCI).
    Summary · context
    Patients were stratified into 2 comparable groups in compliance with the specifics of therapy: 55 patients were treated with cerebrolysin and 55 - with cavinton.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with mild cognitive impairment, cerebrolysin delayed transition to Alzheimer's disease more than cavinton.

    In plain wordsIn patients with mild cognitive impairment, cerebrolysin delayed transition to Alzheimer's disease more than cavinton.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseTime to Alzheimer's disease transition
    Study

    n = 110

    Comparator
    Cavinton
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The superiority of cerebrolysin over cavinton in slowing down of the cognitive deficit progression and delaying the time or transition of patients to the diagnostic category of Alzheimer's disease was demonstrated.
    2 context sentences
    Summary · context
    The total sample included 110 patients whose mental state met the definition of <> (MCI).
    Summary · context
    Patients were stratified into 2 comparable groups in compliance with the specifics of therapy: 55 patients were treated with cerebrolysin and 55 - with cavinton.
  3. 03HumanNon-randomized trialSafety outcome

    In patients with mild cognitive impairment, adverse effects were rare in both the cerebrolysin and cavinton groups.

    In plain wordsIn patients with mild cognitive impairment, side effects were rare with both cerebrolysin and cavinton.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedAdverse effects
    Study

    n = 110

    Comparator
    Cavinton
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Adverse effects during the treatment were rare in both groups.
    2 context sentences
    Summary · context
    The total sample included 110 patients whose mental state met the definition of <> (MCI).
    Summary · context
    Patients were stratified into 2 comparable groups in compliance with the specifics of therapy: 55 patients were treated with cerebrolysin and 55 - with cavinton.
  4. 04HumanNon-randomized trialEfficacy outcome

    In mild cognitive impairment patients with ApoE(+) genotype, the study reported particularly effective cerebrolysin treatment without a separate outcome estimate.

    In plain wordsIn patients with mild cognitive impairment and ApoE(+) genotype, the study described cerebrolysin as particularly effective but gave no separate outcome estimate.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedEffectiveness in ApoE(+) subgroup
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cerebrolysin was particularly effective in MCI patients with the ApoE(+) genotype, i.e. in those with higher risk for Alzheimer's disease.
    2 context sentences
    Summary · context
    The total sample included 110 patients whose mental state met the definition of <> (MCI).
    Summary · context
    Patients were stratified into 2 comparable groups in compliance with the specifics of therapy: 55 patients were treated with cerebrolysin and 55 - with cavinton.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.